Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses increasing prognostic uncertainty in light of targeted treatments and immunotherapies, and the difficulty predicting who will benefit.
Joseph A. Greer, PhD, of Massachusetts General Hospital, discusses the development of a mobile application to address treatment adherence and symptoms (Abstract 104).
Tracy A. Balboni, MD, MPH, of the Dana-Farber Cancer Institute, talks about how to preserve quality of life in the presence of complex spinal lesions, including novel ways to assess spinal instability and treat metastases.
Areej El-Jawahri, MD, of Massachusetts General Hospital, discusses ways in which palliative care can reduce symptoms, improve quality of life, reduce depression and anxiety, and potentially optimize end-of-life care for patients with hematologic malignancies.
Charles F. von Gunten, MD, PhD, of OhioHealth, discusses hospice care as a measure of quality, and findings that show medical oncologists doubled the median length of hospice service from 20 days to 40 days (Abstract 45).
Stephen T. Sonis, DMD, DMSc, of Dana-Farber Cancer Institute, discusses the epidemiology, pathogenesis, and scope of oral complications of radiation therapy.
